Laurus Labs delivered a substantial improvement in profitability for the first quarter of FY26, reporting a consolidated net profit after tax and share of profit from associates and joint ventures of ₹362.07 crore. This represents a sharp increase from ₹161.68 crore recorded in Q1FY25. The surge was underpinned by a 29.1% year-on-year growth in revenue from operations, which rose to ₹2,026.31 crore from ₹1,569.57 crore in the corresponding prior period. Strong operational execution and favorable pricing dynamics contributed to the expanded margins, positioning the company for a robust start to the fiscal year.

The Board of Directors approved the unaudited standalone and consolidated financial results at a meeting held on July 24, 2026, in Hyderabad. The approval was made pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells LLP, the statutory auditors, conducted a limited review of the interim financial information in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India. The auditors issued an unmodified conclusion, stating that nothing came to their attention to suggest the statements did not comply with Indian Accounting Standards (Ind AS) or contained material misstatements.

Financial Performance Overview

The company’s financial metrics reflect consistent growth across key parameters. Standalone net profit after tax stood at ₹289.96 crore, compared to ₹157.94 crore in Q1FY25. Revenue from operations on a standalone basis reached ₹1,757.16 crore, up from ₹1,432.75 crore in the previous year’s quarter. The following table details the consolidated financial highlights:

Total comprehensive income for the consolidated group amounted to ₹359.86 crore, compared to ₹160.97 crore in Q1FY25. The profit attributable to equity holders of the company was ₹367.60 crore. Earnings per share (basic) increased to ₹6.81 from ₹3.02 in the prior year quarter.

Corporate Developments and Restructuring

Laurus Labs continues to advance its strategic restructuring initiatives. The Board had previously approved a Composite Scheme of Arrangement on August 21, 2025, involving the demerger of the identified business undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited. The remaining undertaking of Laurus Synthesis is set to amalgamate with the parent company. The scheme has been filed with the National Company Law Tribunal (NCLT), Amaravathi Bench, under Sections 230 and 232 of the Companies Act, 2013. Implementation remains subject to final approvals from the NCLT, with an appointed date proposed as April 01, 2026. Pending these approvals, the financial results are presented without giving effect to the merger.

During the quarter ended June 30, 2026, the company allotted 393,001 equity shares of ₹2 each following the exercise of stock options by employees under the Employee Stock Option Scheme. The paid-up equity share capital stands at ₹108.05 crore. The group includes wholly-owned subsidiaries such as Laurus Holdings Limited (UK), Laurus Generics Inc. (USA), and Laurus Synthesis Private Limited (India), alongside associates like ImmunoAdoptive Cell Therapy Private Limited and Ethan Energy India Private Limited.

What the Numbers Show

The divergence between revenue growth and expense management highlights improved operational efficiency. While total expenses rose to ₹1,554.13 crore from ₹1,355.78 crore in Q1FY25, the profit before tax more than doubled to ₹481.36 crore from ₹224.22 crore. This indicates that the growth in top-line revenue outpaced the increase in cost of materials consumed and employee benefits, leading to expanded operating leverage. The effective tax rate remained stable, with total tax expense at ₹119.37 crore against a pre-tax profit of ₹481.36 crore. The strong bottom-line performance underscores the resilience of the pharmaceutical segment amidst global market dynamics.

Laurus Labs Limited delivered a robust financial performance in the first quarter of FY27, reporting a 29% year-on-year revenue increase to ₹2,026 crore and a 126% jump in net profit to ₹368 crore. The strong results were primarily driven by a 67% surge in Contract Development and Manufacturing Organization (CDMO) revenues, which reached ₹870 crore, offsetting modest growth in the Affordable Medicines segment. This top-line expansion translated into significant bottom-line gains, with earnings per share (EPS) rising 127% to ₹6.8 from ₹3.0 in the corresponding period last year.

The filing, submitted to the Bombay Stock Exchange and National Stock Exchange on July 24, 2026, highlights an EBITDA increase of 66% to ₹644 crore, representing an expanded margin of 31.8%, up from 24.8% in Q1FY26. Gross margins also widened by 330 basis points to 62.7%. Management attributed these improvements to enhanced CDMO revenue contributions, better divisional mix, and improved capacity utilization. The company maintained its aggressive investment trajectory, with capital expenditure standing at ₹394 crore, or 19% of sales, focused heavily on API/CDMO capabilities and advanced biologics infrastructure.

Financial Performance Highlights

Segmental Breakdown

The CDMO segment emerged as the primary growth engine, with small molecules revenue soaring 69% to ₹835 crore, driven by steady progression of late-stage clinical projects and commercial API supplies. The Bio segment achieved 21% year-on-year growth to ₹35 crore. In contrast, the Affordable Medicines segment recorded total revenue of ₹1,156 crore, up 10% year-on-year. Within this segment, Finished Dosage Forms (FDF) revenue grew 22% to ₹502 crore, while API revenue remained relatively flat at ₹654 crore.

What the Numbers Show

A critical observation from the Q1FY27 results is the structural shift in Laurus Labs’ revenue composition. The CDMO segment now accounts for 43% of total revenue (combining small molecules and bio), compared to approximately 33% in the prior year. This diversification is reducing reliance on the cyclical Affordable Medicines business. Furthermore, the simultaneous expansion in both gross margins (to 62.7%) and operating margins (to 31.8%) indicates that the higher-margin CDMO mix is not only driving volume but also significantly enhancing profitability efficiency. Total R&D investments, including capex R&D, rose 74% year-on-year to ₹118 crore (5.8% of revenue), reflecting heavy development efforts toward building Advanced Biologics infrastructure for Gene Therapy and Antibody Drug Conjugates (ADCs).

Strategic Initiatives and Capex

Laurus Labs continues to invest in high-growth areas, with over 85% of its capex directed toward growth projects. Key initiatives include expanding fermentation manufacturing capacity in Vizag, expected to be commissioned by Q3FY27, and advancing commercial-scale peptide production. In advanced biologics, the company in-licensed two ADC assets from Aarvik Therapeutics and is building a manufacturing facility for gene therapy and ADCs, with qualification expected by end-2027. Additionally, the second GMP production facility for cell therapy in Navi Mumbai became operational in March 2026, boosting treatment capacity to over 2,500 units.

The company also reaffirmed its environmental, social, and governance (ESG) commitments, having received Science Based Targets initiative (SBTi) validation for its near-term greenhouse gas reduction targets. These include a 42% absolute reduction in Scope 1 and 2 emissions by FY31 and a 51.6% intensity reduction in Scope 3 emissions. With a net leverage ratio stable at 1.3x and a healthy order book, Laurus Labs appears well-positioned to sustain its growth momentum through FY27.